The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated squirrel monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 3, 2005, Pages 1257-1266

  Stephenson, Diane T ^a,d   Meglasson, Martin D ^d   Connell, Mark A ^b   Childs, Mary A ^b   Hajos Korcsok, Eva ^a   Emborg, Marina E ^c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b University of Wisconsin ^*

^c LIGAND PHARMACEUTICALS INC   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIPARKINSON AGENT; CARBIDOPA PLUS LEVODOPA; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; ROPINIROLE; SUMANIROLE; TRANSCRIPTION FACTOR FOSB; U 95666E;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY REACTION; ARTICLE; ASTROCYTOSIS; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DYSKINESIA; IMMUNOCOMPETENT CELL; MALE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

ANIMALS; BASAL GANGLIA; BENZIMIDAZOLES; BIOGENIC MONOAMINES; DOPAMINE AGONISTS; LEVODOPA; MALE; MOTOR ACTIVITY; MPTP POISONING; RECEPTORS, DOPAMINE D2; SAIMIRI; SUBSTANTIA NIGRA;

EID: 23944445894     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.087379     Document Type: Article

References (52)

1. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda EB, Lee EJ, Cool MH, Sibley DR, et al. (1996) A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 93:1945-1949.
2. Baik JH, Picetti R, Saiardi A, Thiriet G, Dierich A, Depaulis A, Le Meur M, and Borrelli E (1995) Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature (Lond) 377:424-428.
3. Bezard E, Brotchie J, and Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2:577-588.
4. Boyce S, Rupniak NM, Steventon MJ, and Iversen SD (1990) Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol 13:448-458.
5. Bozzi Y and Borrelli E (1999) Absence of the dopamine D2 receptor leads to a decreased expression of GDNF and NT-4 mRNAs in restricted brain areas. Eur J Neurosci 11:1275-1284.
6. Brefel C, Thalamas C, Rayet S, Lopez-Gil A, Fitzpatrick K, Bullman S, Citerone DR, Taylor AC, Montastruc JL, and Rascol O (1998) Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. Br J Clin Pharmacol 45:412-415.
7. Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, and Frackowiak RS (1992) Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 31:184-192.
8. Calabresi P, Saiardi A, Pisani A, Baik JH, Centonze D, Mercuri NB, Bernardi G, and Borrelli E (1997) Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors. J Neurosci 17:4536-4544.
9. Camacho-Ochoa M, Hoffmann WE, Moon MW, Figure LM, Tang AH, Himes CS, Nichols NF, and Piercey MF (1995) Presynaptic and postsynaptic pharmacology of U-95666A, a dopamine agonist selective for the D2 receptor subtype: increase in post-synaptic response in Parkinson's disease model. Society Neurosci Abstr 21:853.
10. Cenci MA, Tranberg A, Andersson M, and Hilbertson A (1999) Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 94:515-527.
11. Doucet JP, Nakabeppu Y, Bedard PJ, Hope BT, Nestler EJ, Jasmin BJ, Chen JS, Iadarola MJ, St-Jean M, Wigle N, et al. (1996) Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci 8:365-381.
12. D'Souza GA, Didier E, Carel BJ, and Schaaf LJ (2002) Non-compartmental pharmacokinetic analysis of sumanirole in Parkinson's disease patients. European Federation of Neurological Societies Annual Meeting; 2002 Oct 28; pp 105-161, poster P2047.
13. Durham RA, Eaton MJ, Moore KE, and Lookingland KJ (1997) Effects of selective activation of dopamine D2 and D3 receptors on prolactin secretion and the activity of tuberoinfundibular dopamine neurons. Eur J Pharmacol 335:37-42.
14. Eden RJ, Costall B, Domeney AM, Gerrard PA, Harvey CA, Kelly ME, Naylor RJ, Owen DA, and Wright A (1991) Preclinical pharmacology of ropinirole (SK&F 101468-A), a novel dopamine D2 agonist. Pharmacol Biochem Behav 38:147-154.
15. Emilien G, Maloteaux JM, Geurts M, Hoogenberg K, and Cragg S (1999) Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacol Ther 84:133-156.
16. Emmers R and Akert K (1963) A Stereotaxic Atlas of the Brain of the Squirrel Monkey (Saimiri sciureus), University of Wisconsin Press, Madison.
17. Fukuzaki K, Kamenosono T, Kitazumi K, and Nagata R (2000) Effects of Ropinirole on motor behavior in MPTP-treated common marmosets. Pharmacol Biochem Behav 67:121-129.
18. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, and Sibley DR (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science (Wash DC) 250:1429-1432.
19. Graham WC, Sambrook MA, and Crossman AR (1993) Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in monkey brain in MPTP-induced Parkinsonism. Brain Res 602:290-303.
20. Grondin R, Hadj Tahar A, Doan VD, Ladure P, and Bedard PJ (2000) Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn-Schmiedeberg's Arch Pharmacol 361:181-186.
21. Gurevich EV and Joyce JN (1999) Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20:60-80.
22. Harder S and Baas H (1998) Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. Clin Pharmacol Ther 64:183-191.
23. Henry B, Fox SH, Peggs D, Crossman AR, and Brotchie JM (1999) The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances antiparkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 14:744-753.
24. Hope BT, Nye HE, Kelz MB, Self DW, Iadarola MJ, Nakabeppu Y, Duman RS, and Nestler EJ (1994) Induction of a long-lasting AP-1 complex composed of altered fos-like proteins in brain by chronic cocaine and other treatments. Neuron 13:1235-1244.
25. Joyce J (2001) Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharm Ther 90:231-259.
26. Joyce JN, Marshall JF, Bankiewicz KS, Kopin IJ, and Jacobowitz DM (1986) Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phyenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density. Brain Res 382:360-364.
27. Langston JW and Ballard P (1984) Parkinsonian induced by MPTP: implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci 11:160-165.
28. Langston JW, Quik M, Petzinger G, Jakowec M, and Di Monte DA (2000) Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann Neurol 47:S79-S89.
29. Lundblad M, Vaudano E, and Cenci MA (2003) Cellular and behavioural effects of the adenosine A2a1 receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia. J Neurochem 84:1398-1410.
30. Maratos EC, Jackson MJ, Pearce RK, Cannizzaro C, and Jenner P (2003) Both short and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp Neurol 179:90-102.
31. McCall RB, Lookingland KJ, Bédard PJ, and Huff RM (2005) Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease. J Pharmacol Exp Ther 314:1248-1256.
32. Palfi S, Leventhal L, Goetz CG, Hantraye T, Roitberg BZ, Sramek J, Emborg M, and Kordower JH (2000) Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys. Mov Disord 15:524-530.
33. Parish CL, Finkelstein DI, Drago J, Borelli E, and Horne MK (2001) The role of dopamine receptors in regulating the size of axonal arbors. J Neurosci 21:5147-5157.
34. Pearce RK, Banerji T, Jenner P, and Marsden CD (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-DOPA in the MPTP-treated marmoset. Mov Disord 13:234-241.
35. Perez-Otano I, Mandelzys A, and Morgan JI (1998) MPTP-Parkinsonism is accompanied by persistent expression of a delta-FosB-like protein in dopaminergic pathways. Brain Res Mol Brain Res 53:41-52.
36. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, and Lang AE (2000) A five year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484-1491.
37. Robertson GS, Vincent SR, and Fibiger HC (1992) D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience 49:285-296.
38. Rubinstein M, Phillips TJ, Bunzow JR, Falzone TL, Dziewczapolski G, Zhang G, Fang Y, Larson JL, McDougall JA, Chester JA, et al. (1997) Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine and methamphetamine. Cell 90:991-1001.
39. Russ H, Mihatsch W, Gerlach M, Riederer P, and Przuntek H (1991) Neurochemical and behavioral features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease? Neurosci Lett 123:115-118.
40. Schapira AH and Olanow CW (2003) Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann Neurol 53:S149-S159.
41. Sethy VH, Ellerbrock BR, and Wu H (1997) U-95666E: a potential anti-parkinsonian drug with anxiolytic activity. Prog Neuropsychopharmacol Biol Psychiatry 21:873-883.
42. Silverdale MA, Nicholson SL, Ravenscroft P, Crossman AR, Millan MJ, and Brotchie JM (2004) Selective blockade of D3 dopamine receptors enhances the antiparkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Exp Neurol 188:128-138.
43. Sonnenberg JL, Rauscher FJ 3rd, Morgan JI, and Curran T (1989) Regulation of proenkephalin by Fos and Jun. Science (Wash DC) 246:1622-1625.
44. Stephenson DT, Li Q, Simmons C, Connell MA, Meglasson MM, Merchant KM, and Emborg ME (2005) Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration. Neurobiol Dis, in press.
45. Tekumalla PK, Calon F, Rahman Z, Birdi S, Rajput AH, Hornykiewicz O, Di Paolo T, Bedard PJ, and Nestler EJ (2001) Elevated levels of deltaFosB and RGS9 in striatum in Parkinson's disease. Biol Psychol 50:813-816.
46. Thornburg JE and Moore KE (1975) Supersensitivity to dopamine agonists following unilateral, 6-hydroxydopamine-induced striatal lesions in mice. J Pharmacol Exp Ther 192:42-49.
47. Tohgi H, Abe T, Takahashi S, Takahashi J, and Hamato H (1993) Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease and their changes after L-dopa administration. Neurosci Lett 159:135-138.
48. Ware JA DSG, Zhong WZ, Guyton ME, Schaaf LS, and Duncan JN (2002) Evaluation of sumanirole pharmacokinetics in nonclinical species, human volunteers and patients with Parkinson's disease: evidence of linear pharmacokinetics across species. Eur J Neurol 9 (Suppl 2):123.
49. Westin JE, Andersson M, Lundblad M, and Cenci MA (2001) Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur J Neurosci 14:1171-1176.
50. Wikberg T (1991) Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J Pharm Biomed Anal 9:167-176.
51. Wooten G (2003) Agonists vs levodopa in PD. Neurology 60:360-362.
52. Zigmond MJ and Stricker EM (1980) Supersensitivity after intraventricular 6-hydroxydopamine: relation to dopamine depletion. Experientia 36:436-438.